Bio-Bridge Science Announces the Appointment of Mitchell Kronenberg, Ph.D. to its Scientific Advisory Board
November 07 2008 - 8:24AM
Business Wire
Bio-Bridge Science, Inc. (OTCBB:BGES), a biotechnology company
engaged in the commercial development of vaccines for the
prevention and treatment of human infectious diseases, announced
the appointment of Dr. Mitchell Kronenberg to the Scientific
Advisory Board of the Company. Dr. Kronenberg is an internationally
recognized leading expert on NKT cells and mucosal immunology. He
has over 230 highly cited publications, is currently on the Finance
Committee of the American Association of Immunologists and serves
as a Deputy Editor for the Journal of Immunology. Dr. Kronenberg
was named a Roy and Robert Kroc Distinguished Visiting Professor of
Immunology and Medicine by the University of California, Davis in
2000, and was a Borroughs Wellcome Fund Visiting Professor at
Harvard University in 2002. Dr. Liang Qiao, Chairman and CEO of
Bio-Bridge Science, commented, �We are very pleased to work with
Dr. Kronenberg. His expertise and experience in immunology is
widely respected and we look forward to receiving his valuable
advice and recommendations.� Dr. Kronenberg joins Dr. Katherine
Knight, Chairperson and Professor of Microbiology and Immunology at
Loyola University Chicago and past President of the American
Association of Immunologists, on the Scientific Advisory Board of
Bio-Bridge Science. This press release contains forward-looking
statements. Forward-looking statements include statements
concerning plans, objectives, goals, strategies, future events or
performance, and underlying assumptions and other statements that
are other than statements of historical facts. These statements are
subject to uncertainties and risks including, but not limited to,
product and service demand and acceptance, changes in technology,
economic conditions, the impact of competition and pricing,
government regulation, and other risks defined in this document and
in statements filed from time to time with the Securities and
Exchange Commission. All such forward-looking statements, whether
written or oral, and whether made by or on behalf of the company,
are expressly qualified by these cautionary statements and any
other cautionary statements which may accompany the forward-looking
statements. In addition, the company disclaims any obligation to
update any forward-looking statements to reflect events or
circumstances after the date hereof. Please refer to the Company's
SEC filings for additional information.
Bio Bridge Science (CE) (USOTC:BGES)
Historical Stock Chart
From Jun 2024 to Jul 2024
Bio Bridge Science (CE) (USOTC:BGES)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Bio Bridge Science Inc (CE) (OTCMarkets): 0 recent articles
More Bio-Bridge Science, Inc. News Articles